Paper Details

  1. Home
  2. Paper Details

ASP2151 for the treatment of genital herpes: a randomized, double-blind, placebo- and valacyclovir-controlled, dose-finding study.

Author: DhaddaShobha, RorigRamona, TakenouchiKazumasa, TyringStephen, WaldAnna, ZadeikisNeddie

Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

ASP2151 was effective and safe in treating episodes of recurrent genital herpes.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Current therapies for genital herpes have only partial efficacy. Helicase-primase inhibitors are novel, potent inhibitors of herpes simplex virus replication. METHODS: This randomized trial assessed the safety and efficacy of ASP2151 for episodic therapy of recurrent genital herpes. Par...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1093/infdis/jis019

データ提供：米国国立医学図書館（NLM）

ASP2151 for Genital Herpes: A Promising New Treatment Option

The field of infectious disease research is always seeking better ways to combat viruses, and this study focuses on a new treatment for genital herpes. It's like a race against time, where the researchers are looking for the quickest and most effective way to stop the virus from spreading. The study investigates the efficacy and safety of ASP2151, a novel helicase-primase inhibitor, in treating recurrent genital herpes.

ASP2151 Shows Promise in Treating Genital Herpes

The results are promising, with ASP2151 demonstrating efficacy in shortening the time to lesion healing. It's like a desert oasis, offering relief from the burning sensation of herpes symptoms. The study also found that ASP2151 was well-tolerated, a crucial aspect of any new treatment. The researchers are excited about the potential of ASP2151 as a safe and effective treatment for genital herpes.

Navigating the Desert of Herpes: A New Treatment Approach

ASP2151 represents a potential breakthrough in the fight against genital herpes. Its efficacy in reducing symptom duration and its favorable safety profile make it a promising candidate for future treatment options. It's like finding a new, reliable source of water in the desert, offering hope for better management of this common and often challenging condition.

Dr. Camel's Conclusion

ASP2151 shows great promise as a new treatment option for genital herpes, offering quicker relief and a better chance of healing. It's like a camel finding a new, reliable source of water in the desert, offering hope for a more comfortable journey through the challenges of this condition.
Date :
  1. Date Completed 2012-04-30
  2. Date Revised 2018-12-01
Further Info :

Pubmed ID

22351940

DOI: Digital Object Identifier

10.1093/infdis/jis019

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.